Literature DB >> 20332023

Alzheimer's disease: old problem, new views from transgenic and viral models.

Tomasz Jaworski1, Ilse Dewachter, Claire Marie Seymour, Peter Borghgraef, Herman Devijver, Sebastian Kügler, Fred Van Leuven.   

Abstract

Alzheimer's dementia is developing ever more as a complex syndrome with various unknown genetic and epigenetic contributions. These are compounded on and exacerbating the underlying amyloid and tau pathology that remain the basis of the pathological definition of Alzheimer's disease. Here, we present a selection of aspects of recent bigenic and virus-based mouse strains, developed as pre-clinical models for Alzheimer's disease. We discuss newer features in the context of the characteristics defined in previously validated transgenic models. We focus on specific aspects of single and multiple transgenic mouse models for Alzheimer's disease and for tauopathies, rather than providing an exhaustive list of all available models. We concentrate on the content of information related to neurodegeneration and disease mechanisms. We pay attention to aspects and defects that are predicted by the models and can be tested in humans. We discuss implications that help translate the fundamental knowledge into clinical, diagnostic and therapeutic applications. We elaborate on the increasing knowledge extracted from transgenic models and from newer adeno-associated viral models. We advocate this combination as a valuable strategy to study molecular, cellular and system-related pathogenic mechanisms in AD and tauopathies. We believe that innovative animal models remain needed to critically test current views, to identify and validate therapeutic targets, to allow testing of compounds, to help understand and eventually treat tauopathies, including Alzheimer's disease.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20332023     DOI: 10.1016/j.bbadis.2010.03.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 3.  The supramolecular chemistry of β-sheets.

Authors:  Pin-Nan Cheng; Johnny D Pham; James S Nowick
Journal:  J Am Chem Soc       Date:  2013-04-02       Impact factor: 15.419

4.  GSK-3α/β kinases and amyloid production in vivo.

Authors:  Tomasz Jaworski; Ilse Dewachter; Benoit Lechat; Maarten Gees; Anna Kremer; David Demedts; Peter Borghgraef; Herman Devijver; Seb Kügler; Satish Patel; Jim R Woodgett; Fred Van Leuven
Journal:  Nature       Date:  2011-12-07       Impact factor: 49.962

Review 5.  The Government's role in regulating, coordinating, and standardizing the response to Alzheimer's disease: Anticipated international cooperation in the area of intractable and rare diseases.

Authors:  Qi Tang; Peipei Song; Lingzhong Xu
Journal:  Intractable Rare Dis Res       Date:  2016-11

Review 6.  Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology.

Authors:  M Obulesu; R Venu; R Somashekhar
Journal:  Neurochem Res       Date:  2011-04-21       Impact factor: 3.996

7.  Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.

Authors:  Chiou-Miin Wang; Sarah Devries; Marybeth Camboni; Matthew Glass; Paul T Martin
Journal:  Neurobiol Dis       Date:  2010-05-20       Impact factor: 5.996

8.  Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease.

Authors:  Tomasz Jaworski; Sebastian Kügler; Fred Van Leuven
Journal:  Int J Alzheimers Dis       Date:  2010-08-24

9.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

10.  Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.

Authors:  Ann Van der Jeugd; Katja Hochgräfe; Tariq Ahmed; Jochen M Decker; Astrid Sydow; Anne Hofmann; Dan Wu; Lars Messing; Detlef Balschun; Rudi D'Hooge; Eva-Maria Mandelkow
Journal:  Acta Neuropathol       Date:  2012-04-25       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.